CD56neg CD16+ cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML
Taken together, our results suggest that we could harness CD56neg CD16+ NK cells cytotoxic potential in vitro to restore NK cell anti-tumor response in AML patients with CD56neg CD16+ NK cells expansion and improve patients' prognosis. To conclude, CD56neg CD16+ NK cells represent a relevant target for future NK-cell-based immunotherapies in AML.
Authors
- Marie-Sarah Rouviére (ORCID: https://orcid.org/0000-0002-7139-7362)
- Amira Ben Amara (ORCID: https://orcid.org/0009-0000-8210-0846)
- Daniel Olive (ORCID: https://orcid.org/0000-0003-1299-4113)
- Florence Orlanducci
- Philippe Livrati
- Laurent Gorvel (ORCID: https://orcid.org/0000-0001-7526-261X)
- Norbert Vey (ORCID: https://orcid.org/0000-0001-7027-040X)
- Raynier Devillier
- Nicolas Dulphy (ORCID: https://orcid.org/0000-0002-1243-6456)
- Manon Richaud (ORCID: https://orcid.org/0009-0001-7807-9770)
- Anne-Sophie Chrétien (ORCID: https://orcid.org/0000-0003-4685-5568)
- Clémence Demerle
- Julia Wlosik
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Université Paris Cité (FR)
- Sorbonne Paris Cité (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Immunité et Cancer (FR)
- Centre de Recherche en Cancérologie de Marseille (FR)
- Hôpital Saint-Louis (FR)
- Institut Paoli-Calmettes (FR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-01-10
- DOI
- https://doi.org/10.3389/fimmu.2024.1487792
- Citations
- 7
- Primary Topic
- Immune Cell Function and Interaction
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- Association Laurette Fugain